Free Trial

Alto Neuroscience (ANRO) Stock Price, News & Analysis

Alto Neuroscience logo
$11.06 -0.13 (-1.12%)
As of 03:56 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Alto Neuroscience Stock (NYSE:ANRO)

Advanced

Key Stats

Today's Range
$10.92
$11.95
50-Day Range
$3.15
$11.15
52-Week Range
$1.60
$12.19
Volume
304,210 shs
Average Volume
645,086 shs
Market Capitalization
$299.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00
Consensus Rating
Moderate Buy

Company Overview

Alto Neuroscience Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
54th Percentile Overall Score

ANRO MarketRank™: 

Alto Neuroscience scored higher than 54% of companies evaluated by MarketBeat, and ranked 839th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Alto Neuroscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Alto Neuroscience has a consensus price target of $19.00, representing about 65.1% upside from its current price of $11.51.

  • Amount of Analyst Coverage

    Alto Neuroscience has only been the subject of 4 research reports in the past 90 days.

  • Read more about Alto Neuroscience's stock forecast and price target.
  • Earnings Growth

    Earnings for Alto Neuroscience are expected to grow in the coming year, from ($2.54) to ($2.39) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Alto Neuroscience is -4.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Alto Neuroscience is -4.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Alto Neuroscience has a P/B Ratio of 2.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Alto Neuroscience's valuation and earnings.
  • Percentage of Shares Shorted

    6.86% of the float of Alto Neuroscience has been sold short.
  • Short Interest Ratio / Days to Cover

    Alto Neuroscience has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • Dividend Yield

    Alto Neuroscience does not currently pay a dividend.

  • Dividend Growth

    Alto Neuroscience does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.86% of the float of Alto Neuroscience has been sold short.
  • Short Interest Ratio / Days to Cover

    Alto Neuroscience has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • News Sentiment

    Alto Neuroscience has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 29 news articles for Alto Neuroscience this week, compared to 8 articles on an average week.
  • Search Interest

    25 people have searched for ANRO on MarketBeat in the last 30 days. This is an increase of 213% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Alto Neuroscience to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Alto Neuroscience insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.13% of the stock of Alto Neuroscience is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Alto Neuroscience's insider trading history.
Receive ANRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alto Neuroscience and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ANRO Stock News Headlines

"I'm risking my reputation on this"
The Fed rate cut truth they don't want you to know The Fed's 25 basis point cut isn't just monetary policy… it's the starting gun for what I'm calling the "Great Crypto Revolution."tc pixel
See More Headlines

ANRO Stock Analysis - Frequently Asked Questions

Alto Neuroscience's stock was trading at $4.23 on January 1st, 2025. Since then, ANRO shares have increased by 172.0% and is now trading at $11.5050.

Alto Neuroscience, Inc. (NYSE:ANRO) posted its quarterly earnings data on Wednesday, August, 13th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by $0.08.

Alto Neuroscience (ANRO) raised $129 million in an initial public offering (IPO) on Friday, February 2nd 2024. The company issued 8,040,000 shares at $16.00 per share.

Shares of ANRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alto Neuroscience investors own include JPMorgan Chase & Co. (JPM), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

Last Earnings
8/13/2025
Today
10/24/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:ANRO
Previous Symbol
NYSE:ANRO
CIK
1999480
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

High Price Target
$16.00
Low Price Target
$4.00
Potential Upside/Downside
-1.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.39)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$61.43 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-44.34%
Return on Assets
-36.73%

Debt

Debt-to-Equity Ratio
0.18
Current Ratio
18.43
Quick Ratio
18.43

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.62 per share
Price / Book
1.98

Miscellaneous

Outstanding Shares
27,080,000
Free Float
24,063,000
Market Cap
$301.89 million
Optionable
N/A
Beta
2.00

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NYSE:ANRO) was last updated on 10/24/2025 by MarketBeat.com Staff
From Our Partners